Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Depreciation and Depletion (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Depreciation and Depletion for 7 consecutive years, with $20000.0 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Depreciation and Depletion fell 61.54% year-over-year to $20000.0, compared with a TTM value of $78000.0 through Dec 2019, down 70.11%, and an annual FY2024 reading of $318000.0, up 2.25% over the prior year.
  • Depreciation and Depletion was $20000.0 for Q4 2019 at Larimar Therapeutics, roughly flat from $20000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $107000.0 in Q3 2018 and bottomed at -$13000.0 in Q2 2019.
  • Average Depreciation and Depletion over 5 years is $40450.0, with a median of $49000.0 recorded in 2016.
  • The sharpest move saw Depreciation and Depletion soared 900.0% in 2016, then plummeted 125.0% in 2019.
  • Year by year, Depreciation and Depletion stood at $43000.0 in 2015, then skyrocketed by 41.86% to $61000.0 in 2016, then decreased by 18.03% to $50000.0 in 2017, then grew by 4.0% to $52000.0 in 2018, then crashed by 61.54% to $20000.0 in 2019.
  • Business Quant data shows Depreciation and Depletion for LRMR at $20000.0 in Q4 2019, $20000.0 in Q3 2019, and -$13000.0 in Q2 2019.